IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis

Journal of Allergy and Clinical Immunology

Volumn 140, Issue 1, 2017, Pages 109-120

  Johnston, Andrew ^a   Xing, Xianying ^a   Wolterink, Liza ^a   Barnes, Drew H ^a   Yin, ZhiQiang ^a,d   Reingold, Laura ^a   Kahlenberg, J Michelle ^b   Harms, Paul W ^a,c   Gudjonsson, Johann E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Generalized pustular psoriasis; inflammation; interleukin; psoriasis

Indexed keywords

CATHEPSIN G; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; ELASTASE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 36; INTERLEUKIN 36ALPHA; INTERLEUKIN 36GAMMA; INTERLEUKIN 8; PROTEINASE INHIBITOR; SERPIN A1; SERPIN A3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; MESSENGER RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE ONTOLOGY; GENERALIZED PUSTULAR PSORIASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTE; MICROARRAY ANALYSIS; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; UPREGULATION; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; PSORIASIS; SKIN;

CELLS, CULTURED; CYTOKINES; HUMANS; KERATINOCYTES; NEUTROPHILS; PSORIASIS; RNA, MESSENGER; SKIN;

EID: 85010549528     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.08.056     Document Type: Article

References (49)

1. Gudjonsson, J.E., Elder, J.T., Psoriasis., 8th ed. Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K., (eds.) Fitzpatrick's dermatology in general medicine, chapter 18, 2012, McGraw-Hill Medical, New York, NY.
2. Hussain, S., Berki, D.M., Choon, S.E., Burden, A.D., Allen, M.H., Arostegui, J.I., et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 135 (2015), 1067–1070.e9.
3. Onoufriadis, A., Simpson, M.A., Pink, A.E., Di Meglio, P., Smith, C.H., Pullabhatla, V., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 89 (2011), 432–437.
4. Setta-Kaffetzi, N., Navarini, A.A., Patel, V.M., Pullabhatla, V., Pink, A.E., Choon, S.E., et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 133 (2013), 1366–1369.
5. Sugiura, K., Takemoto, A., Yamaguchi, M., Takahashi, H., Shoda, Y., Mitsuma, T., et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 133 (2013), 2514–2521.
6. Robinson, A., Van Voorhees, A.S., Hsu, S., Korman, N.J., Lebwohl, M.G., Bebo, B.F. Jr., et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 67 (2012), 279–288.
7. Hodgin, J.B., Borczuk, A.C., Nasr, S.H., Markowitz, G.S., Nair, V., Martini, S., et al. A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol 177 (2010), 1674–1686.
8. Dai, M., Wang, P., Boyd, A.D., Kostov, G., Athey, B., Jones, E.G., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res, 33, 2005, e175.
9. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 (2003), 249–264.
10. Johnson, W.E., Li, C., Rabinovic, A., Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8 (2007), 118–127.
11. Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34 (2003), 374–378.
12. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550.
13. Swindell, W.R., Stuart, P.E., Sarkar, M.K., Voorhees, J.J., Elder, J.T., Johnston, A., et al. Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era. BMC Med Genomics, 7, 2014, 27.
14. Swindell, W.R., Johnston, A., Voorhees, J.J., Elder, J.T., Gudjonsson, J.E., Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics, 14, 2013, 527.
15. Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25 (2009), 1091–1093.
16. Clark, R.A., Nauseef, W.M., Isolation and functional analysis of neutrophils. Curr Protoc Immunol, chapter 7, 2001, unit 7.23.
17. Henry, C.M., Sullivan, G.P., Clancy, D.M., Afonina, I.S., Kulms, D., Martin, S.J., Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep 14 (2016), 708–722.
18. Macleod, T., Doble, R., McGonagle, D., Wasson, C.W., Alase, A., Stacey, M., et al. Neutrophil elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist. Sci Rep, 6, 2016, 24880.
19. Law, R.H., Zhang, Q., McGowan, S., Buckle, A.M., Silverman, G.A., Wong, W., et al. An overview of the serpin superfamily. Genome Biol, 7, 2006, 216.
20. Schmitt, J., Rosumeck, S., Thomaschewski, G., Sporbeck, B., Haufe, E., Nast, A., Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 170 (2014), 274–303.
21. Leonardi, C.L., Romiti, R., Tebbey, P.W., Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin 33 (2015), 111–125.
22. Marrakchi, S., Guigue, P., Renshaw, B.R., Puel, A., Pei, X.Y., Fraitag, S., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 365 (2011), 620–628.
23. Korber, A., Mossner, R., Renner, R., Sticht, H., Wilsmann-Theis, D., Schulz, P., et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol 133 (2013), 2634–2637.
24. Setta-Kaffetzi, N., Simpson, M.A., Navarini, A.A., Patel, V.M., Lu, H.C., Allen, M.H., et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 94 (2014), 790–797.
25. Jordan, C.T., Cao, L., Roberson, E.D., Pierson, K.C., Yang, C.F., Joyce, C.E., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 90 (2012), 784–795.
26. Johnston, A., Xing, X., Guzman, A.M., Riblett, M., Loyd, C.M., Ward, N.L., et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 186 (2011), 2613–2622.
27. Blumberg, H., Dinh, H., Trueblood, E.S., Pretorius, J., Kugler, D., Weng, N., et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204 (2007), 2603–2614.
28. Debets, R., Timans, J.C., Homey, B., Zurawski, S., Sana, T.R., Lo, S., et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 167 (2001), 1440–1446.
29. Carrier, Y., Ma, H.L., Ramon, H.E., Napierata, L., Small, C., O'Toole, M., et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 131 (2011), 2428–2437.
30. Foster, A.M., Baliwag, J., Chen, C.S., Guzman, A.M., Stoll, S.W., Gudjonsson, J.E., et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol 192 (2014), 6053–6061.
31. Mutamba, S., Allison, A., Mahida, Y., Barrow, P., Foster, N., Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol 42 (2012), 607–617.
32. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A.J., et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 122 (2012), 3965–3976.
33. Lefrancais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.P., et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109 (2012), 1673–1678.
34. Lefrancais, E., Duval, A., Mirey, E., Roga, S., Espinosa, E., Cayrol, C., et al. Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 111 (2014), 15502–15507.
35. Snelgrove, R.J., Gregory, L.G., Peiro, T., Akthar, S., Campbell, G.A., Walker, S.A., et al. Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. J Allergy Clin Immunol 134 (2014), 583–592.e6.
36. Towne, J.E., Renshaw, B.R., Douangpanya, J., Lipsky, B.P., Shen, M., Gabel, C.A., et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem 286 (2011), 42594–42602.
37. Rossi-Semerano, L., Piram, M., Chiaverini, C., De Ricaud, D., Smahi, A., Kone-Paut, I., First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 132 (2013), e1043–e1047.
38. Huffmeier, U., Watzold, M., Mohr, J., Schon, M.P., Mossner, R., Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 170 (2014), 202–204.
39. Viguier, M., Guigue, P., Pages, C., Smahi, A., Bachelez, H., Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 153 (2010), 66–67.
40. Tauber, M., Viguier, M., Le Gall, C., Smahi, A., Bachelez, H., Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?. Br J Dermatol 170 (2014), 1198–1199.
41. Elewski, B.E., Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 47 (2002), 796–797.
42. Newland, M.R., Weinstein, A., Kerdel, F., Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41 (2002), 449–452.
43. Johnston, A., Guzman, A.M., Swindell, W.R., Wang, F., Kang, S., Gudjonsson, J.E., Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol 171 (2014), 97–107.
44. Chiricozzi, A., Guttman-Yassky, E., Suarez-Farinas, M., Nograles, K.E., Tian, S., Cardinale, I., et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131 (2011), 677–687.
45. Bohner, A., Roenneberg, S., Eyerich, K., Eberlein, B., Biedermann, T., Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol 152 (2016), 482–484.
46. Imafuku, S., Honma, M., Okubo, Y., Komine, M., Ohtsuki, M., Morita, A., et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 43 (2016), 1011–1017.
47. Yamasaki, K., Nakagawa, H., Kubo, Y., Ootaki, K., Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol, 2016 Apr 23 [E-pub ahead of print].
48. Wolf, J., Ferris, L.K., Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569. Expert Opin Ther Pat 24 (2014), 477–479.
49. Gunther, S., Sundberg, E.J., Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol 193 (2014), 921–930.